DermaXon announces its partnership with VantAI, a Roivant Biosciences Vant company, for the rapid acceleration of two of its drug development programs. VantAI leads the computational drug discovery space with technology at the bleeding edge of machine learning and...
September 2019: DermaXon received a Phase 1 STTR Grant funding from the National Institute of Neurological Disorders and Stroke to support preclinical efficacy studies for a novel drug treatment for pruritus. This award, titled “TOPICAL SELECTIVE T-TYPE BLOCKERS FOR...